

**1<sup>st</sup> International IPIG Conference – 18<sup>th</sup> May 2023**

<b>Time</b>	<b>Session</b>	<b>Lead</b>
07:30	Arrival: drinks & refreshments	
08:00 – 08:10	<b>Welcome address by Antonio M. Risitano President &amp; Chair of the IPIG Board</b>	
<b>08:10 – 10:10</b>	<b>SESSION I. Understanding PNH from its history</b>	<b>Antonio M. Risitano &amp; Petra Muus</b>
08:10 - 08:40	A brief history of PNH & complement	Wendell F. Rosse
08:40 - 09:10	Molecular and biological aspects of the GPI-defect in PNH	Taroh Kinoshita
09:10 - 09:40	Current understanding of the pathophysiology of PNH	Lucio Luzzatto
09:40 - 10:10	Somatic mutation in non-malignant diseases	Neal Young
10:10 - 10:40	Morning Break: drinks and refreshments	
<b>10:40 - 12:05</b>	<b>SESSION II. Complement for hematologists</b>	<b>Morag Griffin &amp; Jun-ichi Nishimura</b>
10:40 - 11:05	Complement biology in PNH	Véronique Frémeaux-Bacchi
11:05 - 11:20	Development of anti-complement agents	Dimitrios Mastellos
11:20 - 11:35	Open discussion: what hematologists want to know about complement	Austin Kulasekararaj (discussant)
11:35 - 11:50	<b>Selected abstracts for oral presentation:</b> Vemircopan (ALXN2050) monotherapy in PNH: interim data from a phase 2 open-label proof-of-concept study	Austin Kulasekararaj
11:50 - 12:05	Population pharmacokinetics of pegcetacoplan in healthy subjects and patients with PNH	Ryan L. Crass
12:05 - 13:00	Lunch	
<b>13:00 - 15:15</b>	<b>SESSION III. PNH treatment: complement inhibitors and beyond</b>	<b>Jaroslawn Maciejewski &amp; Hubert Schrezenmeier</b>
13:00 - 13:30	Anti-C5 as disease modifying treatment	Régis Peffault de Latour
13:30 - 14:00	Upgrading complement inhibition in PNH: the road to proximal inhibitors	Antonio M. Risitano
14:00 - 14:15	Spotlight 1: other treatment options for PNH	Morag Griffin
14:15 - 14:30	Spotlight 2: management of thrombosis in PNH	Richard Kelly
14:30 - 14:45	Round Table Discussion	All
14:45 – 15:15	Afternoon Break: drinks and refreshments	
<b>15:15 – 17:45</b>	<b>SESSION IV. Recent clinical data on complement inhibition in PNH</b>	<b>Russell Ware &amp; Britta Höchsmann</b>
15:15 - 15:30	Ravulizumab, danicopan, vemircopan	Austin Kulasekararaj
15:30 - 15:45	Crovalimab	Jens Panse
15:45 - 16:00	Pegcetacoplan in suboptimal responders	Régis Peffault de Latour
16:00 - 16:15	Pegcetacoplan in the real world: US experience 2 years after approval	Carlos M. De Castro
16:15 - 16:30	Iptacopan	Antonio M. Risitano
16:30 - 16:45	ABP 959	Saskia Langemeijer
16:45 - 17:00	Pozelimab, cemdisiran	Morag Griffin
17:00 - 17:15	SB12	Bruno Fattizzo
17:15 - 17:45	Round Table Discussion	All

**1<sup>st</sup> International IPIG Conference – 18<sup>th</sup> May 2023**

<b>Time</b>	<b>Session</b>	<b>Lead</b>
17:45 – 18:45	<b>SESSION V. Poster Session</b>	<b>Saskia Langemeijer &amp; Bruno Fattizzo</b>
	Oral iptacopan monotherapy increases PNH red blood cell clone size via control of intra- and extravascular hemolysis in anti-C5 treated PNH patients with anemia	Antonio M. Risitano
	Development of KP104, a first-in-class bifunctional antibody fusion protein targeting both terminal and alternative pathways simultaneously as a single agent undergoing Ph2 evaluation of safety and efficacy in naïve PNH patients	Bing Han
	Thrombosis and meningococcal infection rates in pegcetacoplan patients with PNH in the clinical trial and post-marketing settings	Richard Kelly
	Exposure-response analyses of pegcetacoplan in patients with PNH	Ryan L. Crass
	Efficacy and safety of single agent proximal complement inhibitors in PNH patients with residual anemia despite adequate terminal complement inhibitor use	Srinivasa Sanikommu
	Model-informed precision dosing of eculizumab in patients with PNH	Saskia Langemeijer
	Understanding the real-world clinical effectiveness of pegcetacoplan for the treatment of PNH	Brian Mulherin
	Six-month crovalimab extension in the Phase III COMMODORE 3 study: updated efficacy and safety results in complement inhibitor- naïve patients with PNH	Alice C. Chang
<b>19:30</b>	<b>Conference Dinner</b>	

**1<sup>st</sup> International IPIG Conference – 19<sup>th</sup> May 2023**

<b>Time</b>	<b>Session</b>	<b>Lead</b>
07:30	Arrival: drinks & refreshments	
07:55	<b>Welcome - Antonio M. Risitano President &amp; Chair of the IPIG Board</b>	
		<b>Jaroslav Maciejewski &amp; Hubert Schrezenmeier</b>
08:00 - 08:15	<b>Selected abstracts for oral presentation:</b> Phase III randomized multicenter open label COMMODORE 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor experienced patients with PNH	Austin Kulasekararaj
08:15 - 08:30	Efficacy and safety of switching to iptacopan monotherapy in patients with PNH treated with the anti C5 monoclonal antibody tesidolumab	Yasutaka Ueda
<b>08:30 – 10:30</b>	<b>SESSION VI. Hot topics in PNH 2023</b>	<b>Petra Muus, Richard Kelly and Jens Panse</b>
08:30 – 09:00	Defining response & endpoints	Jeff Szer Discussant: Petra Muus
09:00 – 09:30	Breakthrough hemolysis: terminal vs proximal inhibitors	Austin Kulasekararaj Discussant: Richard Kelly
09:30 – 10:00	Proximal inhibitors: monotherapy vs combination treatment	Rosario Notaro Discussant: Jens Panse
10:00 – 10:15	<b>Selected abstracts for oral presentation:</b> Oral factor B iptacopan monotherapy improves Hb to normal/near normal levels in complement inhibitor naïve PNH patients. Phase III APPOINT-PNH trial	Bing Han
10:15 – 10:30	Phase III randomized COMMODORE 2 trial: results from a multicenter study of crovalimab vs eculizumab in PNH patients naïve to complement inhibitors	Alexander Röth
10:30 – 11:00	Morning Break: drinks and refreshments	
<b>11:00 – 13:00</b>	<b>SESSION VII. Worldwide IPIG mission</b>	<b>Jeff Szer &amp; Charles J. Parker</b>
11:00 – 11:15	Registry	Jeff Szer
11:15 – 11:30	PNH in China	Bing Han
11:30 – 11:45	PNH in Turkey & SE Asia Region	Mustafa Yenerel
11:45 – 12:00	PNH in South America	Rodrigo Calado
12:00 – 12:15	PNH in Africa	Lucio Luzzatto
12:15 – 12:30	PNH in Eastern Europe	Jaroslav Čermák
12:30 – 12:45	Guidelines Project	Régis Peffault de Latour
12:45 – 13:00	Summary	Antonio M. Risitano
13:00 – 14:00	Lunch	
<b>14:00</b>	<b>Departures</b>	